Immunotherapies in diabetes mellitus type 1. [electronic resource]
Producer: 20120925Description: 621-34, xi p. digitalISSN:- 1557-9859
- Abatacept
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- Antilymphocyte Serum -- therapeutic use
- Azathioprine -- therapeutic use
- Basiliximab
- Chaperonin 60 -- therapeutic use
- Cyclosporine -- therapeutic use
- Daclizumab
- Diabetes Mellitus, Type 1 -- immunology
- Diet
- Etanercept
- Exenatide
- Fatty Acids, Unsaturated -- therapeutic use
- Glutamate Decarboxylase -- therapeutic use
- Humans
- Hypoglycemic Agents -- immunology
- Immunoconjugates -- therapeutic use
- Immunoglobulin G -- therapeutic use
- Immunosuppressive Agents -- therapeutic use
- Insulin -- immunology
- Interferon-alpha -- therapeutic use
- Interleukin 1 Receptor Antagonist Protein -- therapeutic use
- Islets of Langerhans Transplantation
- Niacinamide -- therapeutic use
- Peptide Fragments -- therapeutic use
- Peptides -- therapeutic use
- Primary Prevention
- Pyrazines -- therapeutic use
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Recombinant Fusion Proteins -- therapeutic use
- Rituximab
- Secondary Prevention
- Sitagliptin Phosphate
- Tertiary Prevention
- Triazoles -- therapeutic use
- Venoms -- therapeutic use
- Vitamin D -- therapeutic use
- Vitamins -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.